Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merus NV

56.21
+0.20000.36%
Post-market: 56.210.00000.00%19:43 EDT
Volume:761.91K
Turnover:43.22M
Market Cap:4.19B
PE:-13.57
High:57.70
Open:56.04
Low:56.01
Close:56.01
Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Merus (MRUS) and Ramsay Health Care (OtherRMSYF)

TIPRANKS
·
28 Feb

Merus FY 2024 GAAP EPS $(3.35) Beats $(3.80) Estimate, Sales $36.133 Miss $38.544M Estimate

Benzinga
·
28 Feb

Merus NV Based On Co's Current Operating Plan, Existing Cash, Cash Equivalents And Marketable Securities Expected To Fund Merus' Operations Into 2028

Reuters
·
28 Feb

Merus to Present at Upcoming Investor Conferences

GlobeNewswire
·
25 Feb

Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab

MT Newswires Live
·
18 Feb

Merus’ petosemtamab granted Breakthrough Therapy designation by FDA

TIPRANKS
·
18 Feb

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

GlobeNewswire
·
13 Feb

Piper Sandler Initiates Merus at Overweight With $84 Price Target

MT Newswires Live
·
13 Feb

Analyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue Potential

TIPRANKS
·
13 Feb

Merus initiated with an Overweight at Piper Sandler

TIPRANKS
·
13 Feb

Wells Fargo Initiates Merus at Overweight With $91 Price Target

MT Newswires Live
·
07 Feb

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

GlobeNewswire
·
06 Feb

Bank of America Securities Sticks to Its Buy Rating for Merus (MRUS)

TIPRANKS
·
14 Jan

Biohaven enters multi-target collaboration with Merus

TIPRANKS
·
14 Jan

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

MT Newswires Live
·
13 Jan

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

Insider Monkey
·
08 Jan

Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial

MT Newswires Live
·
17 Dec 2024

Merus doses first patient in petosemtamab trial

TIPRANKS
·
17 Dec 2024

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

GlobeNewswire
·
17 Dec 2024

GILD Obtains Positive CHMP Opinion for Liver Disease Drug

Zacks
·
17 Dec 2024